Abstract
The scientific, private, and industrial sectors use a wide variety of technological platforms available to achieve protection against SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), including vaccines. However, the virus evolves continually into new highly virulent variants, which might overcome the protection provided by vaccines and may re-expose the population to infections. Mass vaccinations should be continued in combination with more or less mandatory non-pharmaceutical interventions. Therefore, the key questions to be answered are: (i) How to identify the primary and secondary infections of SARS-CoV-2? (ii) Why are neutralizing antibodies not long-lasting in both cases of natural infections and post-vaccinations? (iii) Which are the factors responsible for this decay in neutralizing antibodies? (iv) What strategy could be adapted to develop long-term herd immunity? (v) Is the Spike protein the only vaccine target or is a vaccine cocktail better?
| Original language | English |
|---|---|
| Pages (from-to) | 229-237 |
| Number of pages | 9 |
| Journal | Epidemiologia |
| Volume | 3 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published (in print/issue) - 29 Apr 2022 |
Keywords
- SARS-CoV-2
- COVID-19
- variant
- sublineage
- transmission
- immunity
- infection
- vaccination
- non-pharmaceutical interventions
